Smaller shot, same effect? study tests concentrated ABP 501
NCT ID NCT05909852
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a more concentrated version of ABP 501 (a biosimilar to the drug adalimumab) works the same in the body as the standard version. 372 healthy adults received a single injection of either the high-concentration or low-concentration form. Researchers measured drug levels in the blood to see if they were comparable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ABP 501 (a biosimilar to adalimumab)
- What this could lead to
- If successful, this could confirm that a more concentrated version of ABP 501 works just as well as the current one, potentially allowing for smaller injections.
- What could go wrong
- This is an early-phase study in healthy volunteers, not patients. It only measures drug levels in the blood, not actual treatment effects or safety in people with diseases.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADALIMUMAB are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pharmaceutical Research Associates, Inc
Salt Lake City, Utah, 84124, United States
-
Qps-Mra, Llc
South Miami, Florida, 33143, United States
-
WCCT Global, Inc
Cypress, California, 90630, United States